Oriented porous fibrous elastic stent for lymphedema drainage and preparation method thereof
By using fibrous elastic scaffolds containing oriented porous pores in lymphedema treatment, using the combination of natural biomaterials and crosslinking agents and low-temperature ice crystal growth technology, a porous structure suitable for lymphatic regeneration and drainage is solved, and the existing treatment methods are solved. The efficacy of the insignificant efficacy and complex surgery have been solved, which has achieved effective drainage of lymphedema and reconstruction of lymphatic reticulum function.
Patent Information
- Application Number
- CN202410987943.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-15
AI Technical Summary
The existing treatment methods for lymphedema have problems such as lack of obvious efficacy, large surgical damage, and complex operation, and lack suitable clinical alternative treatment plans, especially difficult to achieve a treatment method with little trauma, simple operation and excellent results.
A fibrous elastic scaffold containing oriented porous is used to form a porous structure scaffold with good elasticity and hydrophilicity through mixing natural biomaterials with crosslinking agents and low-temperature ice crystal growth technology, which is used to guide lymphatic regeneration and drainage.
The stent has good mechanical strength and elasticity, can be folded and compressed repeatedly in a wet state and recover quickly. It has stretchability and good liquid drainage effect. It is suitable for drainage and lymphatic regeneration and repair of lymphatic edema, and is suitable for lymphatic tubes. Fine structure realizes the functional reconstruction of the lymph network.
Smart Images

Figure CN118949150A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical tissue repair materials, and relates to a fibrous elastic support containing oriented pores and can be used for lymphedema drainage, and a preparation method thereof. Background Art
[0002] Lymphedema is a lymphatic dysfunction caused by local accumulation of interstitial fluid due to obstruction of lymphatic vessels and insufficient lymphatic drainage caused by factors such as primary developmental abnormalities or secondary destruction of the lymphatic network. It is characterized by chronic swelling of the limbs, head and neck, genitals, etc. [Chen K, Sinelnikov MY, Reshetov IV, et al. Therapeutic potential of mesenchymal stem cells for postmastectomy lymphedema: a literature review [J]. Clin Transl Sci, 2021, 14 (1): 54-61. doi: 10.1111 / cts.12864.]. Globally, about 250 million people are affected by lymphedema. Among them, the most common cause in underdeveloped areas is filariasis. In developed countries, with the significant increase in the incidence of breast cancer, the destruction of the lymphatic network after mastectomy has become the most common cause of iatrogenic lymphedema in clinical practice. According to literature reports, the incidence of upper limb lymphedema in patients undergoing axillary lymph node dissection is as high as 24% to 65% [Rockson SG. Lymphedema after breast cancer treatment[J]. N Engl J Med, 2018, 379(20): 1937-1944. DOI: 10.1056 / NEJMcp1803290.].The discomfort caused by lymphedema can also lead to serious immune-related complications, affect the appearance, significantly reduce the patient's exercise ability and quality of life, and bring great physical and mental burden to the patient [Li K, Xu H, Liu NF, Sadigh P, Evans V, Zhang YX. Far-infrared ray for treating chronic lower extremity lymphedema with dermatolymphangioadenitis: a postoperative complication of gynecological tumor resection [J]. Arch Gynecol Obstet, 2017, 295 (6): 1441-1450. / Chen K, Sinelnikov MY, Reshetov IV, et al. Therapeutic potential of mesenchymal stem cells for postmastectomy lymphedema: a literature review. Clin Transl Sci, 2021, 14 (1): 54-61.]. The prevalence of lymphedema is currently as high as 1.3-1.5 / 1000 worldwide [Schaverien MV, Coroneos CJ. Surgical Treatment of Lymphedema [J]. Plast Reconstr Surg, 2019, 144 (3): 738-758.], and the number of patients in my country alone exceeds 2 million. Therefore, lymphedema is a major clinical problem that needs to be solved in plastic surgery due to its high incidence and severe clinical manifestations.
[0003] The treatment methods for lymphedema are divided into non-surgical treatment and surgical treatment. Non-surgical treatment includes weight loss and exercise, baking and binding therapy, manual drainage, complex physical therapy, interstitial air pressure therapy, low-level laser therapy, VEGF-C therapy, etc. Surgical treatment is a supplement when conservative treatment is ineffective, mainly including lymphatic-venous anastomosis, autologous lymph node / lymphatic vessel / venous transplantation, stem cell transplantation, lesion excision flap transplantation, negative pressure liposuction, etc. However, there is no standardized treatment plan at present, and there are various problems with existing treatment methods. Conservative treatment methods show the disadvantages of slow and complicated treatment process, long treatment cycle, and unobvious efficacy. Surgical treatment often has different efficacy, large surgical damage, and large side effects. In addition, due to the thin diameter of the lymphatic system, the surgical operation is difficult and requires high surgeons. Therefore, there is no suitable treatment for lymphedema as a whole, and it is urgent to propose clinical alternative treatments with less trauma, simpler operation, and better effect.
[0004] At present, the treatment of lymphedema is still in the exploratory stage, and there is no unified treatment plan, which is still a major challenge in the medical community. Although traditional physical methods and microsurgery [MuL, BiY, PengZ, et al. Autologous tissue breast reconstruction and thoracic wall repair with microsurgical lymph node transfers and lymphatic-venous anastomoses for the treatment of mastectomy-related axillary cavity deformation and upper extremity lymphedema [J]. Chin J Plast Surg, 2017, 33 (1): 54-60. DOI: 10.3760 / cma.j.issn.1009-4598.2017.s1.012.] can control the symptoms of lymphedema to a certain extent, there is still no effective way to perform radical treatment. In recent years, with the development of tissue engineering technology, it has had a profound impact on the treatment of lymphedema and also provided a new idea and method for the treatment of lymphedema. The use of stents to connect the gaps between lymphatic vessels and guide the regeneration of functional lymphatic tissue is expected to solve this clinical problem.
[0005] The lymphatic tissue engineering approach aims to combine relevant cell and scaffold components to regenerate lymphatic structures as a potential alternative to surgical treatment that eliminates the risk of morbidity at the lymph node donor site. The development of tissue engineering technology has made it possible for interconnected scaffolds to fill the gaps between lymphatic vessels and guide the regeneration of functional lymphatic tissue. It can be divided into three categories: biodegradable, non-biodegradable, and acellular dermal matrix.
[0006] The earliest non-degradable biological stents can be traced back to Handley, who first proposed placing sterile silk thread subcutaneously in the affected area to promote lymphatic outflow through capillary action [Handley WS. Two cases of lymphangioplasty for the brawny arm of breast cancer. Proc R Soc Med 1908; 1 (Clin Sect): 186-190]; later, Silver and Puckett 1976 used a special Teflon multifilament material to replace the silk thread in their clinical trials [Silver D, Puckett CL. Lymphangioplasty: a ten year evaluation. Surgery 1976; 80 (06) 748-755], and the results showed that the initial drainage effect was significant, suggesting that lymphatic pathway stent drainage is a feasible treatment method. However, the foreign body reaction caused by the low biocompatibility of the stent over a long period of time can cause reduced lymphatic flow and local infection. Recently, the development of biomaterials has made such treatment more possible. A new type of nanocomposite material, polyhedral oligomeric silsesquioxane poly(carbonate-urea)urethane (UCL-Nano), has been proven to be biocompatible, anti-infective and durable [Kannan RY, Salacinski HJ, Sales KM, et al. The endothelialization of polyhedral oligomeric silsesquioxane nanocomposites: an in vitro study [J]. Cell Biochem Biophys, 2006, 45 (2): 129-136. DOI: 10.1385 / cbb:45:2:129.]. Compared with traditional transplant materials, UCL-Nano nanocomposites have thermal stability, biostability and strong mechanical properties, but their bioactivity is relatively poor, which limits their application.
[0007] Commonly used synthetic polymer biomaterials such as polyglycolic acid (PGA) and polycaprolactone (PCL) have good biocompatibility and biodegradability. It has been reported that polyglycolic acid (PGA) scaffolds and LECs were used as seed cells to reconstruct lymphatic vessels, and LECs endothelialization was successfully induced in vitro and in vivo. The tubular structure of the complex has preliminary lymphatic characteristics [SUNGCJ, GUPTAK, WANGJ, et al. Lymphatic Tissue Bioengineering for the Treatment of Postsurgical Lymphedema [J]. Bioengineering, 2022, 9 (4): 162]. However, due to the hydrophobicity of these biomaterials, it is difficult to provide the drainage needs in the early stage of lymphedema treatment, and their poor elasticity makes it difficult to maintain the original porous structure after implantation in the body, making it difficult to guide the regeneration of long-segment lymphatic vessels and the reconstruction of lymphatic network function.
[0008] Natural biomaterials such as acellular dermal matrix (ADM), collagen, silk fibroin, etc. have excellent biocompatibility, biodegradability, and bioactivity, and have been widely used in tissue engineering vascular transplantation reconstruction [Schaner PJ, Martin ND, Tulenko TN, et al. Decellularized vein as a potential scaffold for vascular tissue engineering [J]. J Vasc Surg, 2004, 40 (1): 146-153. DOI: 10.1016 / j.jvs.2004.03.033.]. Wong et al. [Wong AK, Schonmeyer BH, Singh P, et al. Histologic analysis of lymphangiogenesis and lymphangiogenesis in a cellular human dermis [J]. Plast Reconstr Surg, 2008, 121 (4): 1144-1152] implanted ADM as a flap into the superficial upper abdominal wall of rats and observed that the LEC in the experimental group proliferated 4 times, and LEC increased steadily within 14 days and tended to mature and stabilize on the 14th day. This shows that ADM has a good promoting effect on the formation of lymphatic networks. ADM scaffolds can promote LEC proliferation and lymphatic network regeneration to a certain extent. However, since it is a biological product of animal origin, there are still problems such as residual toxic substances, uncontrollable degradation rate, risk of non-autologous disease transmission, and difficulty in standardized quality control. Multifilament nanofiber collagen scaffolds are recently proposed biomaterial bridges for lymphatic restoration (CS; Biobridge, Fibralign Corporation, 32930 Alvarado-Niles Rd 350, Union City, CA 94587, USA). Research results show that such nanofiber scaffolds can provide space for endothelial cells to arrange and grow. At the same time, the scaffold can provide a substrate for endothelial cells to arrange and migrate along collagen fibers. In addition, these multi-cavity scaffolds can provide channels for promoting extracellular fluid reflux.Implantation of such biological scaffolds may achieve therapeutic effects by promoting lymphangiogenesis and drainage [Hadamitzky C, Zaitseva TS, Bazalova-Carter M. et al. Aligned nanofibrillar collagen scaffolds-guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials 2016; 102: 259-267, Lai ES, Huang NF, Cooke JP, Fuller GG. Aligned nanofibrillar collagen regulates to send lymphatic organization and migration. Regen Med 2012; 7 (05) 649-661]. However, due to its simple collagen component, Biobridge material degrades quickly and has poor elasticity, so it cannot maintain its structure for a long time in the body, nor can it achieve long-term drainage and promote lymphatic regeneration. Silk fibroin is a widely used biomedical material with excellent biocompatibility. Its porous scaffold is mainly formed by weak interactions and crystallization of molecular chain β-folding, but its mechanical properties and elasticity are weak and it is difficult to resist the dynamic mechanical environment in the body and maintain structural stability. In addition, due to the delicate organizational structure of lymphatic vessels (between 0.1 mm and 0.3 cm), it is difficult to prepare a delicate porous scaffold with an oriented channel structure to adapt to the anastomosis of lymphatic vessels and achieve the purpose of drainage and lymphatic regeneration.
[0009] At present, the treatment of lymphedema is still in the exploratory stage, and there is no unified treatment plan, which is still a major challenge in the medical community. Although traditional physical methods and microsurgery can control the symptoms of lymphedema to a certain extent, there is still no effective way to perform radical treatment. With the development of tissue engineering and regenerative medicine, new ideas have been provided for the reconstruction of normal lymphatic networks, but there is still a lack of related products. The key to whether the scaffold can be widely used lies in: ① hydrophilic and containing oriented porous structures to have good immediate drainage effects; ② adapting to the diameter size of the lymphatic vessel fine structure; ③ good elasticity to resist dynamic stress in the body and maintain morphological structure stability; ④ promoting the attachment of lymphatic endothelial cells and promoting the regeneration of lymphatic network. Summary of the invention
[0010] The present invention is directed to the above-mentioned problems and provides a fibrous elastic scaffold containing oriented pores that can be used for lymphedema drainage and a preparation method thereof. The technical idea of the present invention is as follows: natural biological materials are mixed with a cross-linking agent and placed in a reaction container of a preset shape, and the growth state of ice crystals is controlled by controlling the low temperature, the contact method between the container and the low temperature source, additives, etc. One-way contact with the low temperature source can make the ice crystals grow in an orderly manner to form an oriented microchannel porous structure inside the fibrous scaffold; when the whole is placed in a low temperature environment, the ice crystals grow in an integrated disordered manner to form an irregular porous structure inside the fibrous scaffold.
[0011] To achieve the above object, the present invention adopts the following technical solution:
[0012] In a first aspect, the present invention provides a method for preparing an oriented porous fibrous elastic scaffold that can be used for lymphedema drainage, comprising the following steps: mixing a natural biological material and a cross-linking agent in a certain proportion and placing the mixture in a reaction vessel of a preset shape, contacting one end of the reaction vessel with a low-temperature medium so that ice crystals grow from one end to the other end until the solution in the tube is completely frozen, and during the growth of the ice crystals, the natural biological material and the cross-linking agent in the solution gradually precipitate onto the surface of the ice crystals; continuing to freeze, while maintaining the ice crystal structure, the natural biological material is physically and chemically cross-linked at the same time; then standing at room temperature, the ice crystals melt, further completing the physical and chemical cross-linking to form an elastic porous fibrous scaffold, further removing the reaction residues and the cross-linking agent by washing, and preparing a dry porous fibrous elastic scaffold by freeze-drying.
[0013] Preferably, the natural biomaterial is selected from any one or more combinations of silk fibroin, collagen, gelatin, chitosan, and acellular dermal matrix;
[0014] Preferably, the crosslinking agent is selected from any one of epoxy crosslinking agents such as ethylene glycol diglycidyl ether (EDGE), butanediol diglycidyl ether (BDGE), hexanediol diglycidyl ether (HDK), polyethylene glycol diglycidyl ether (PEGGE), etc.
[0015] Preferably, the material of the reaction container is a glass tube, such as a capillary glass tube, an acrylic glass tube, a polytetrafluoroethylene glass tube, etc.; in terms of shape, the shape of the reaction container can be designed according to the target shape of the fiber support, such as a tubular shape, an S shape, a Y shape, a dendritic multi-branched grid shape, etc.
[0016] Preferably, the temperature of the cryogenic medium is not higher than -10°C, preferably liquid nitrogen commonly used in laboratories; the freezing temperature is further between -20°C and -5°C, and the freezing time is 12-36 hours; the standing time at room temperature is adjusted as needed, generally 12-24 hours, to further complete physical and chemical cross-linking to form an elastic porous fibrous scaffold.
[0017] Preferably, during the reaction, depending on the rapidity of the reaction between the material and the cross-linking agent, a nucleating agent may be added to the solution to promote ice crystal growth, or an inhibitor (such as DMSO, glycerol, etc.) may be added to inhibit ice crystal growth, thereby controlling the morphology of the ice crystals to achieve the purpose of controlling the porous structure.
[0018] Preferably, the stent can also be loaded with drugs or active factors (such as VEGF, etc.) through physical or chemical means to enhance the biological activity and functionality of the stent.
[0019] In the specific implementation of the present invention, taking the natural biomaterial silk fibroin as an example, the epoxy crosslinking agent ethylene glycol diglycidyl ether (EDGE) is used as a crosslinking agent to describe the preparation process of the fibrous elastic scaffold containing oriented porous. The specific process is as follows:
[0020] The concentration of the silk fibroin solution is 1-30wt%, and the crosslinking agent is added at a ratio of 0.5-10mmol of crosslinking agent per gram of silk fibroin and then mixed. The solution is filled into a glass tube reaction container of a preset size or shape by capillary action and reacted therein, and one end of the reaction container is contacted with a low temperature (liquid nitrogen or other low-temperature medium) so that ice crystals grow from one end to the other end until the solution in the tube is completely frozen. During the growth of the ice crystals, the silk fibroin and the crosslinking agent in the solution gradually precipitate onto the surface of the ice crystals. The solution is frozen (-20°C to -5°C) for 12-36 hours, and the silk fibroin generates β-folding and epoxy crosslinking while maintaining the ice crystal structure, and is gradually formed; the solution is left standing at room temperature for 12-24 hours, and the ice crystals melt the silk fibroin to further complete physical and chemical crosslinking, forming an elastic porous fibrous scaffold, and the oriented growth ice crystals melt to form an oriented channel structure (porous channel size range: 1-100μm). The reaction residues and crosslinking agent are further removed by washing, and a dry silk fibroin elastic porous fibrous scaffold is prepared by freeze drying.
[0021] Specifically, the cleaning method is as follows: the stent is first placed in an ethanol / water solution (ethanol concentration range 10-75%), and ultrasonically or stirred for cleaning 1-3 times, each time for 10 minutes to 1 hour; then placed in deionized water for ultrasonic or stirring cleaning 1-3 times, each time for 10 minutes to 1 hour.
[0022] The freeze-drying conditions are as follows: the scaffold is moistened with deionized water or placed in deionized water, and is frozen at -80 to -20°C for 1 to 24 hours until completely frozen; it is transferred to a freeze dryer and freeze-dried at 5 to 500 Pa vacuum for 24 to 72 hours until the moisture in the scaffold is completely removed.
[0023] In a second aspect, the present invention provides an oriented porous fiber elastic scaffold prepared according to the above method, and in particular provides a silk fibroin elastic porous fiber scaffold. The scaffold has a fiber-like appearance, a length of 5mm-20cm, a diameter range of 0.05-3mm, and a porosity range of 50-95%.
[0024] The scaffold has a double cross-linked network of β-fold physical cross-linking and epoxy chemical cross-linking, which improves the mechanical strength and makes the scaffold have good elasticity. It can be repeatedly folded and compressed in a wet state, with a compression strain of up to 80%, and can quickly return to its original state when in contact with a water environment again; at the same time, the scaffold is stretchable, and the tensile strain can exceed 100%. In addition, the scaffold has good hydrophilicity, and under the capillary action of the microchannels or micropores inside the scaffold, it has a drainage effect on aqueous solutions, tissue fluids, lymph, blood and other liquids. It can be used for lymph drainage of lymphedema, and can also be used for regeneration and repair of other tissues, such as peripheral nerves and blood vessels.
[0025] Therefore, the third aspect of the present invention provides the use of the above-mentioned oriented porous fibrous elastic scaffold in tissue regeneration and repair, wherein the tissue repair includes lymphedema drainage and lymphatic regeneration and repair, peripheral nerve repair, vascular repair, etc.
[0026] Preferably, the use of a silk fibroin elastic porous fibrous scaffold in lymphedema drainage and lymphatic regeneration and repair is provided.
[0027] The fourth aspect of the present invention provides a lymphedema drainage and lymphatic regeneration and repair component, which mainly includes the above-mentioned silk fibroin elastic porous fibrous scaffold.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention takes silk fibroin as an example and provides a new method for preparing a fibrous elastic scaffold. The silk fibroin porous scaffold prepared by the method not only retains its excellent tissue compatibility and biodegradability, but also improves its mechanical strength and makes the scaffold have good elasticity. The scaffold can be repeatedly folded and compressed in a wet state, and the compression strain can reach 80%. It can quickly return to its original state when it contacts the water environment again; at the same time, the scaffold is stretchable, and the tensile strain can exceed 100%, which can completely resist the dynamic mechanical environment in the body and has a stable structure.
[0030] In terms of hydrophilicity, the capillary action of the microchannels or micropores inside the stent has the function of draining aqueous solutions, tissue fluids, lymph fluids, blood and other liquids, and can be used for lymphatic drainage of lymphedema; through microsurgery, the stent can be anastomosed with the broken ends of the defective lymphatic vessels to guide the growth and connection of the lymphatic network, and achieve lymphatic network regeneration and functional reconstruction. In addition, the stent can also be used for the regeneration and repair of other tissues, such as peripheral nerves and blood vessels.
[0031] In addition, since the shape and size of the reaction container can be adjusted during the preparation of the scaffold, a fine porous scaffold with an oriented channel structure can be prepared according to the fine tissue structure of the lymphatic vessels (between 0.1 mm and 0.3 cm) to adapt to the anastomosis of the lymphatic vessels and achieve the purpose of drainage and lymphatic regeneration. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Schematic diagram of the preparation method of the silk fibroin elastic porous fibrous scaffold of the present invention, (A) capillary loading of silk fibroin-crosslinking agent mixed solution, (B) unidirectional frozen ice crystal directional growth, (C) silk fibroin cross-linking formation on the surface of ice crystal, (D) elastic porous fibrous scaffold containing oriented channels;
[0033] Figure 2 The morphological evaluation of the elastic porous fibrous scaffold of the silk fibroin of the present invention is shown: (A) multiple fibrous silk scaffolds are in a stretched state in an aqueous solution; (B, C) the silk scaffold has a certain stretchability and elasticity, and can return to its original shape after the stress is removed; (DG) the silk scaffold can be repeatedly compressed and folded in the air, and can quickly stretch, open and return to its original shape after being put into water again.
[0034] Figure 3 The electron microscope images of the silk fibroin elastic porous fibrous scaffold of the present invention are shown: (AC) scaffold surface porous structure, magnification 250, 3000, 7500. (DE) scaffold interface porous structure, magnification 250, 3000, 7500;
[0035] Figure 4 The appearance and liquid drainage function of the elastic porous fibrous scaffold of silk fibroin of the present invention are shown: (A) porous fibrous silk scaffold; (BD) drainage function of the porous fibrous silk scaffold: B: dripping blue dye on the left side of the scaffold, C: 1 minute after dripping the blue dye, the blue dye is drained to the right along the pipeline, D: 3 minutes after dripping the blue dye, the blue dye is drained to the right along the pipeline to the right side of the pipeline.
[0036] Figure 5The figure shows the drainage effect of the hind limbs with lymphedema membrane after implantation of the elastic porous fibrous scaffold of silk fibroin: (A) Image of the lymphatic vessels of the hind limbs, with blue methylene blue staining in the ducts (indicated by the arrow); (B) The part of the external porous fibrous silk scaffold, which shows the blue dye drainage effect immediately after implantation (indicated by the arrow); (C) 30 minutes after implantation, the dye gradually covers the material, indicating that the material has good drainage properties.
[0037] Figure 6 Shown is the determination of local VEGF-C concentration in the material after implantation of silk fibroin elastic porous fibrous scaffold. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] 1. Preparation of elastic porous fibrous scaffolds of silk fibroin
[0040] Epoxy crosslinker (ethylene glycol diglycidyl ether, EDGE) was used as a crosslinker to form a double crosslinked network of β-folded physical crosslinking and chemical crosslinking in the silk fibroin scaffold. The concentration of the silk fibroin solution was (1-30wt%), and 0.5-10mmol of crosslinker was added per gram of silk fibroin. Figure 1 As shown, the preparation method comprises: using capillary action to fill the solution with different sizes of capillary glass tubes (0.1-3 mm) and react therein (1A), contacting one end of the capillary with liquid nitrogen so that ice crystals grow from one end to the other end until the solution in the tube is completely frozen, and the silk and cross-linking agent in the solution gradually precipitate onto the surface of the ice crystals during the growth of the ice crystals (1B). Continue freezing (-20°C to -5°C) for 12-36 hours, while maintaining the ice crystal structure, the silk fibroin produces β-folding and epoxy cross-linking and gradually forms (1C); standing at room temperature for 12-24 hours, the ice crystals melt the silk fibroin to further complete physical and chemical cross-linking, forming an elastic porous fibrous scaffold, and the directional growth of the ice crystals melts to form an oriented channel structure (porous channel size range: 1-100 μm) (1D). Further, the reaction residues and catalysts are removed by washing, and a dry fibrous silk porous scaffold is prepared by freeze drying.
[0041] 2. Performance Testing
[0042] 1. Appearance and elastic properties
[0043] The scaffold has a fibrous appearance, a length of 5mm-20cm, a diameter range of 0.05-3mm, and a porosity range of 50-95%. The above preparation can realize the mass production of porous fibrous silk scaffolds, more than 100 scaffolds can be prepared at a time, and the stability is good. Figure 2 The morphological evaluation of the elastic porous fibrous scaffold of the silk fibroin of the present invention is shown. Multiple fibrous silk scaffolds are in a stretched state in an aqueous solution (2A); the scaffold has a certain stretchability and elasticity, can be stretched more than 1 times, and can return to its original state after the stress is removed (2B, C), which can meet the necessary suturing, fixation and other operations in vivo transplantation, and can cope with the local stretching caused by local limb movement; in addition, the silk scaffold can be repeatedly compressed and folded in the air, and can quickly stretch, open and return to its original state after being put into water again (2D-G), thereby ensuring that the original structure is maintained in the dynamic stress and liquid environment of in vivo implantation.
[0044] 2. Microstructure
[0045] Figure 3 The electron microscope image of the silk fibroin elastic porous fibrous scaffold of the present invention is shown: a large number of micropores are distributed on the surface and inside of the scaffold, the pores are distributed along the axial orientation, the pore size range is 1-15μm, and nanometer-level small holes are distributed on the pore wall surface. These micropore structures have a good drainage effect under capillary action.
[0046] 3. Hydrophilicity
[0047] The drainage effect of porous fibrous silk scaffolds was verified in vitro by drainage experiments. Figure 4 As shown, when a blue droplet is added to one end of the stent, the dye can, without external force, use the hydrophilicity of the stent in capillary action to make the water-soluble dye flow from the high concentration direction to the low concentration direction in the microchannel network and eventually fill the entire stent, indicating that the porous fibrous silk scaffold has good directional material transport and liquid drainage functions.
[0048] 4. Animal model experiments
[0049] The technical effect of the present invention was verified in a rat hind limb lymphedema model. A rat hind limb lymphatic injury model was established, and the material was implanted immediately after membrane formation. The rat hind limb lymphatic injury model was achieved by resecting the lymphatic vessels in the thigh area of the hind limb. After cutting off the lymphatic vessels, the methylene blue dye injected subcutaneously in the rat hind limb could not flow back through the hind limb lymphatic vessels, proving that the membrane of the hind limb lymphatic injury model was successfully formed. The material of the present invention was implanted at the same time as the modeling, and the porous fibrous silk scaffold material was used to replace the damaged lymphatic vessels using microsuturing technology to reconstruct local lymphatic return. The local dye drainage and local cytokine deposition after the material was implanted were observed to evaluate the material effect.
[0050] like Figure 5It can be seen that the porous fibrous silk scaffold showed good drainage characteristics immediately after being sutured into the lymphatic defect area. The methylene blue dye injected subcutaneously in the rat's hind limb gradually infiltrated the porous fibrous silk scaffold, and the scaffold changed from its original white to light blue, and then to dark blue, indicating that after the material was implanted, the lymph fluid blocked locally by lymphedema was able to return. The results of local tissue sections showed that new tissue structures surrounding the material were visible in the tissue, indicating that the material has good biocompatibility. Long-term testing showed that drainage along the lymphatic vessels continued to exist stably, suggesting that local lymphangiogenesis may exist. Hind limb tissue sections showed that compared with the lymphedema control group without material placement, after the first-stage placement of the material, there was no obvious swelling in the local limbs, less subcutaneous lipid deposition, and a mild degree of skin fibrosis. Local cytokine detection showed that after the material intervention, the lymphogenesis-related cytokine (VEGF-C) increased compared with the control group ( Figure 6 ). The scaffold can be used to relieve lymphedema, promote lymphatic regeneration, and achieve functional reconstruction of the lymphatic network.
[0051] In summary, the silk fibroin elastic porous fibrous scaffold prepared in this embodiment has a fibrous appearance, a length of 5mm-20cm, a diameter range of 0.05-3mm, and a porosity range of 50-95%. The shape of the scaffold after molding can be controlled by the shape of the reaction vessel, such as a multi-branched structure. The interior of the scaffold has a porous structure caused by the growth of ice crystals, and the growth state of the ice crystals can be controlled by controlling the low temperature, contact mode, additives, etc. Unidirectional contact with a low-temperature source can make the ice crystals grow in an orderly manner to form an oriented microchannel porous structure inside the fibrous scaffold; when the whole is placed in a low-temperature environment, the ice crystals grow in an integrated and disordered manner, forming an irregular porous structure inside the fibrous scaffold.
[0052] EDGE can form a chemical bond with the amino and hydroxyl groups of silk fibroin to form a stable cross-linked structure; the scaffold has a double cross-linked network of β-folded physical cross-linking and epoxy chemical cross-linking, which improves the mechanical strength and makes the scaffold have good elasticity. It can be repeatedly folded and compressed in a wet state, with a compression strain of up to 80%, and can quickly return to its original state when exposed to water again; the scaffold is stretchable, and the tensile strain can exceed 100%.
[0053] The stent has good hydrophilicity. Under the capillary action of the microchannels or micropores inside the stent, it has the function of draining aqueous solutions, tissue fluids, lymph fluids, blood and other liquids. It can be used for lymphatic drainage of lymphedema. Through microsurgery, the stent can be anastomosed with the broken ends of the defective lymphatic vessels to guide the growth and connection of the lymphatic network, and achieve lymphatic network regeneration and functional reconstruction. In addition, the stent can also be used for the regeneration and repair of other tissues, such as peripheral nerves and blood vessels.
[0054] At the same time, the scaffold has good biocompatibility, including cell compatibility and tissue compatibility, and also has good biodegradability, and can be completely degraded and metabolized in the body. The scaffold can construct endothelialized lymphatic tissue through active factor loading and in vitro cell culture, and then treat lymphedema and repair defects.
[0055] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A method for preparing a fibrous elastic scaffold containing oriented porous fibers, characterized in that: The method comprises the following steps: mixing a natural biological material and a cross-linking agent in a certain proportion and placing the mixture in a reaction vessel of a preset shape; contacting one end of the reaction vessel with a low-temperature medium so that ice crystals grow from one end to the other end until the solution in the tube is completely frozen, and during the growth of the ice crystals, the natural biological material and the cross-linking agent in the solution gradually precipitate onto the surface of the ice crystals; continuing to freeze, while maintaining the ice crystal structure, the natural biological material is physically and chemically cross-linked; then standing at room temperature, the ice crystals melt, and the physical and chemical cross-linking is further completed to form an elastic porous fibrous scaffold; removing the reaction residues and the cross-linking agent by washing, and preparing a dry porous fibrous elastic scaffold by freeze-drying.
2. The method for preparing the oriented porous fibrous elastic scaffold according to claim 1, characterized in that: in, The natural biomaterial is selected from any one or more combinations of silk fibroin, collagen, gelatin, chitosan, and acellular dermal matrix; The cross-linking agent includes any one of the epoxy cross-linking agents ethylene glycol diglycidyl ether EDGE, butanediol diglycidyl ether BDGE, hexanediol diglycidyl ether HDK, and polyethylene glycol diglycidyl ether PEGGE; The concentration of the biomaterial solution is 1-30 wt %, and the cross-linking agent is added at a ratio of 0.5-10 mmol of cross-linking agent per gram of biomaterial; The reaction container includes a capillary glass tube, an acrylic glass tube, and a polytetrafluoroethylene glass tube; the shape of the reaction container is designed according to the target shape of the fiber support.
3. The method for preparing the oriented porous fibrous elastic scaffold according to claim 1, characterized in that: in, The temperature of the low-temperature medium is not higher than -10°C; when freezing continues, the temperature is between -20°C and -5°C, and the freezing time is 12-36 hours; the standing time at room temperature is 12-24 hours, and the physical and chemical cross-linking is further completed to form an elastic porous fibrous scaffold.
4. The method for preparing the oriented porous fibrous elastic scaffold according to claim 1, characterized in that: in, The stent cleaning method is as follows: the stent is first placed in a 10-75% ethanol / water solution, and ultrasonically or stirred for cleaning 1-3 times, each time for 10 minutes to 1 hour; then placed in deionized water for ultrasonic or stirring cleaning 1-3 times, each time for 10 minutes to 1 hour; The freeze-drying conditions are as follows: the scaffold is moistened with deionized water or placed in deionized water, and is frozen at -80 to -20°C for 1 to 24 hours until completely frozen; it is transferred to a freeze dryer and freeze-dried at 5 to 500 Pa vacuum for 24 to 72 hours until the moisture in the scaffold is completely removed.
5. The method for preparing the oriented porous fibrous elastic scaffold according to claim 1, characterized in that: Also includes: The step of loading drugs or active factors on the porous fibrous elastic scaffold.
6. The method for preparing the oriented porous fibrous elastic scaffold according to claim 1, characterized in that: The oriented porous fibrous elastic scaffold is a silk fibroin elastic porous fibrous scaffold, and the preparation method is as follows: The concentration of the silk fibroin solution is 1-30wt%, and a cross-linking agent is added at a ratio of 0.5-10mmol of cross-linking agent per gram of silk fibroin, followed by mixing; the solution is filled into a glass tube reaction container of a preset size or shape by using capillary action and reacted therein, and ice crystals are grown from one end to the other end by contacting one end of the reaction container with low temperature until the solution in the tube is completely frozen, and the silk fibroin and the cross-linking agent in the solution are gradually precipitated onto the surface of the ice crystals during the growth of the ice crystals; the freezing is continued at -20°C to -5°C for 12-36 hours, and while maintaining the ice crystal structure, the silk fibroin generates β-folding and epoxy cross-linking to gradually take shape; the solution is allowed to stand at room temperature for 12-24 hours, and the ice crystals melt the silk fibroin to further complete physical and chemical cross-linking to form an elastic porous fibrous scaffold, and the directionally grown ice crystals melt to form a porous oriented channel structure with a channel size range of 1-100μm; the reaction residues and the cross-linking agent are further removed by washing, and a dry silk fibroin elastic porous fibrous scaffold is prepared by freeze-drying.
7. A fibrous elastic support containing oriented porous material, characterized in that: The method is prepared by any one of claims 1 to 6.
8. Use of the oriented porous fibrous elastic scaffold according to claim 7 in tissue regeneration and repair, characterized in that: Tissue regeneration and repair include lymphedema drainage and lymphatic regeneration and repair, peripheral nerve repair, and vascular repair.
9. Use of the silk fibroin elastic porous fibrous scaffold according to claim 6 in lymphedema drainage and lymphatic regeneration and repair.
10. A lymphedema drainage and lymphatic regeneration repair component, characterized in that It mainly comprises the oriented porous fibrous elastic support as described in claim 7.
